LONDON--(BUSINESS WIRE)--The British-based international niche pharmaceutical business AMCo has opened an office in Dubai as part of its expansion into the healthcare market in the Middle East and North Africa.
AMCo already has distributors in the region but believes an office closer to the countries in which it works will give healthcare workers and hospitals better access to a wider selection of its medicines.
AMCo’s Chief Commercial Officer Steve Higgins said: “We have chosen Dubai for our new office in the MENA region because of the country’s extensive transport links, communications and global reach. We have an ongoing relationship with the healthcare sector in the region. This is part of our expansion plan for the company.
“We are looking at hiring healthcare professionals, sales staff and distributors as part of that plan to enhance and widen our reach. The Dubai office will be the hub for our work across the Middle East and North Africa.”
AMCo’s product range includes treatments for patients with thyroid problems, through to the eye disease conjunctivitis which is common in the Middle East. Mr Higgins said: “We will be closer to the people we want to help and to the doctors, nurses and pharmacists who are looking for cost-effective ways of treating patients.”
Countries in the Middle East, including Saudi Arabia, Kuwait and the United Arab Emirates, have a mix of private and public healthcare.
AMCo operates in 112 countries and has recently expanded its product range to include the medicine, Fucithalmic which treats conjunctivitis. 30 per cent of worldwide sales of the treatment are in the Middle East. If untreated, the disease can cause blindness in severe cases.
The Dubai office will be headed up buy AMCo’s Middle East and North Africa general manager Werner Rooseboom. Mr Rooseboom has extensive experience of the pharmaceutical industry in the region.
For more information please go to: www.amcolimited.com